In recent news, Revance announced the publication of findings in Neurology from the pivotal phase 3 ASPEN-1 trial (NCT03608397) assessing daxibotulinumtoxinA-Ianm (Daxxify), an FDA-approved treatment for cervical dystonia.1,2 All told, these results provided evidence that Daxxify reduces dystonia more effectively than placebo in adults with moderate-to-severe idiopathic cervical dystonia.3
The approval of the expanded indication in August 2023 was based on results from ASPEN-1 and its open-label study (OLS; NCT03617367), which included 382 patients and 1240 treatments over an 88-week time span. In ASPEN-1 both the 125- and 250-unit dose groups of daxibotulinumtoxinA met the primary end point of clinically meaningful improvement in the signs and symptoms of cervical dystonia, on average, by weeks 4 and 6. Additionally, the 125- and 250-unit treatment groups showed improvements of 12.7 and 10.9 points, respectively, on Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) vs the placebo group, which recorded changes of 4.3 (P <.001 and P = .0006, respectively).3
Top Clinical Takeaways
- Daxxify, an FDA-approved treatment, demonstrated superior efficacy over placebo in reducing cervical dystonia symptoms in adults.
- Results from both the ASPEN-1 trial and its open-label study indicate sustained improvement with successive treatments and a favorable safety profile for Daxxify.
- The expanded indication for Daxxify offers a promising advancement in cervical dystonia treatment, potentially reducing symptom reoccurrence between injections.
“As an investigator in all stages of the ASPEN program and a participating physician in the Daxxify cervical dystonia PrevU program, I’m happy to see publication of the pivotal study results in a peer-reviewed journal for the neurology community,” coauthor Atul Patel, MD, MHSA, physiatrist and vice president at Kansas City Bone & Joint Clinic, said in a statement.1 “Importantly, the real-world clinical results of Daxxify from the patients I have injected so far in PrevU, including safety, efficacy and duration, are in-line with those seen in the ASPEN-1 study. By offering a long duration of treatment effect, Daxxify can help reduce symptom reoccurrence between injections, which is experienced by most patients being treated with conventional botulinum toxins. This would represent a significant advancement in the treatment of cervical dystonia, something we have not seen in decades.”
READ MORE: Potential of mGluR5 Modifier ALX-001 in Neurodegenerative Disorders
In the double-blind trial, which spanned 36 weeks, secondary end points, or 2-point improvement on Clinical Global Impression of Change and Patient Global Impression of Change at week 4 or 6, were both found to be consistent in the treated group, showing statistically significantly greater improvement over placebo (P <.001). Both dosed groups of daxibotulinumtoxinA were generally safe and well-tolerated through week 36, with no recorded serious treatment-related adverse events (AEs) and no dose-dependent increase in AEs as well.